Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Plx Pharma Inc (PLXP)

Plx Pharma Inc (PLXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard(TM) delivery system to...

MHMNF : 54.5000 (unch)
PLXP : 3.25 (unch)
Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective...

MTNB : 0.7910 (+2.49%)
PLXP : 3.25 (unch)
PLx Pharma Inc. Reports Second Quarter 2020 Results and Provides Business Update

--Bioequivalence study of VAZALORE 325 mg on track with top-line data demonstrating bioequivalence to immediate release aspirin--

PLXP : 3.25 (unch)
Housing Starts to be Posted in Canada Next Week

Monday U.S. Economic lookahead Job Openings (June) Featured Earnings Marriott International (NASDAQ:MAR) ...

MAR : 92.99 (+1.80%)
ON : 20.49 (+0.89%)
SEAS : 20.49 (+6.11%)
ABX.TO : 37.08 (+0.46%)
LNDC : 9.34 (+1.74%)
NEPT : 2.15 (-0.46%)
SYY : 62.01 (+0.73%)
HBM.TO : 5.31 (+1.14%)
MEQ.TO : 73.14 (-1.22%)
OSK.TO : 3.44 (-1.71%)
WDO.TO : 12.33 (+0.24%)
YY : 77.09 (-0.91%)
LYFT : 27.53 (+2.84%)
PCOM : 9.40 (-3.24%)
FSZ.TO : 10.22 (+0.89%)
BIR.TO : 1.60 (-1.84%)
SIA.TO : 11.30 (+2.45%)
SPB.TO : 11.87 (+0.08%)
IQ : 23.29 (-2.14%)
MTBC : 8.51 (+2.90%)
WCC : 41.66 (+0.17%)
AQN.TO : 19.01 (+1.77%)
CCL-B.TO : 49.72 (+0.44%)
CAAS : 2.95 (unch)
EFOI : 7.35 (+7.77%)
PLXP : 3.25 (unch)
BTB-UN.TO : 2.78 (+0.36%)
HRX.TO : 9.40 (-0.63%)
SII.TO : 46.08 (-1.39%)
BOS.TO : 17.14 (-0.23%)
MAR.TO : 0.52 (unch)
WEED.TO : 18.94 (-0.37%)
PLC.TO : 27.11 (+0.04%)
PLx Pharma Inc. to Discuss 2020 Second Quarter Financial Results on August 14, 2020 Conference Call and Provide Business Update

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard(TM) delivery system to...

PLXP : 3.25 (unch)
PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. Reports First Quarter 2020 Results

-- Company to begin bioequivalence study of VAZALORE 325 mg dose --

PLXP : 3.25 (unch)
PLx Pharma Inc. to Discuss 2020 First Quarter Financial Results on May 15, 2020 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery system to...

PLXP : 3.25 (unch)
PLx Pharma Inc. Reports Fourth Quarter 2019 Results and Provides Regulatory Update on VAZALORE

-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA --

PLXP : 3.25 (unch)
PLx Pharma Inc. to Discuss 2019 Fourth Quarter and Full Year Financial Results on March 13, 2020 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. Presents Original Abstract and Simultaneous Publication of its Novel, Liquid-Filled Capsule Aspirin Formulation at the 2020 International Stroke Conference

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. to Present at Biotech Showcase 2020

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. Provides Regulatory Update on VAZALORE

-- PLx Aligning with the FDA on Data Requirements for VAZALORE

PLXP : 3.25 (unch)
PLx Pharma Inc. Reports Third Quarter 2019 Results

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. to Discuss 2019 Third Quarter Financial Results on November 8, 2019 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. Presents Moderated Abstract and Simultaneous Publication on the Pharmacokinetic and Pharmacodynamics (PK/PD) Properties of its Novel, Liquid Aspirin Formulation at the 2019 European Society of Cardiology Congress

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. to Present at Janney Healthcare Conference 2019 on September 10

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
PLx Pharma Inc. Reports Second Quarter 2019 Results

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)
Earnings Preview: PLx Pharma (PLXP) Q2 Earnings Expected to Decline

PLx Pharma (PLXP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLXP : 3.25 (unch)
PLx Pharma Inc. to Discuss 2019 Second Quarter Financial Results on August 9, 2019 Conference Call

PLx Pharma Inc. (NASDAQ: PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard(TM) delivery...

PLXP : 3.25 (unch)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar